Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with ...

Alector (NASDAQ:ALEC) shares extended post-market losses to drop ~50% in the premarket on Wednesday after the ...

Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; ...

An experimental drug from Alector Inc. failed to slow the decline of patients with frontotemporal dementia in a late-stage ...

The availability of a rule-in-rule-out test for Alzheimer’s disease in primary care settings is likely to drive efficiencies throughout the care continuum.

A nationwide clinical trial is testing whether an existing drug could benefit patients with Alzheimer's disease, in hopes of making symptom-improving medication more accessible for people experiencing ...

A significant challenge in developing therapy and care for Alzheimer’s disease that work for people of different ethnic and racial backgrounds is recruitment and retention of traditionally ...

A team of investigators looked at possible dementia clinical trial requirements that could exclude people based on race and ethnicity. Overall, 82% of the trials they examined had criteria that ...

Before medicines and new treatment methods become available to the public, they undergo clinical trials, which is part of the ...

Credit: Getty Images Clinical trial investigators explore the headway made by diversity, equity, and inclusion initiatives in clinical trials of Alzheimer disease and related dementias and the ...

Neurologists at Florida Atlantic University have launched a new research tool combining focused ultrasound and magnetic ...